Arvinas reported third-quarter 2026 results, cutting costs and extending its cash runway into the second half of 2028. Cash, restricted cash, and marketable securities stood at $558.9 million, down from $685.4 million at the end of 2025. Non-GAAP total expenses fell 25% to $53.5 million from $71.5 million a year earlier. R&D expenses dropped to $46.9 million from $64.7 million, and G&A expenses fell to $12.6 million from $21 million. The company booked its first royalty under the Rigel licence agreement, worth $0.5 million. On the pipeline, the BCL6 degrader ARV-393 will present initial data at ASH, with a second readout in mid-2027. The LRRK2 degrader ARV-102 remains on clinical hold in the US, so its Phase I-B trial will start in Europe. ARV-806 will advance only with a partner.

What investors are watching at arvinas (NASDAQ:ARVN) after a Q3 loss of USD 0.82 per share. 03 November 2026 12:35 PM PST Summarize with AI You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to its research reports, in-depth technical and fundamental research. Learn more Key highlights. * Diluted loss per share of USD 0.82 was narrower than the consensus estimate of a USD 0.88 loss. * Revenue fell to USD 0.5 million from USD 41.9 million, well below the consensus estimate of USD 16.93 million. * Cash and marketable securities totaled USD 558.9 million, down from USD 685.4 million at the end of 2025. * Research and development expense dropped to USD 46.9 million from USD 64.7 million, and general and administrative expense fell 40%. Arvinas, Inc. (NASDAQ:ARVN) reported a third quarter 2026 net loss of USD 53.9 million, or USD 0.82 per diluted share, compared with a net loss of USD 35.1 million, or USD 0.48 per share, a year earlier. The loss per share was narrower than a consensus estimate of a USD 0.88 loss. Revenue of USD 0.5 million, all of it sales-based royalties under the Rigel license agreement, was far below a consensus estimate of USD 16.93 million and the USD 41.9 million booked in the prior year quarter. Spending cuts offset the revenue drop. The prior year revenue figure included USD 20.6 million under the original vepdegestrant collaboration with Pfizer and a USD 20.0 million development milestone tied to the Novartis license. The Pfizer revenue did not recur after all remaining deferred revenue was recognized in the second quarter of 2026, when the Rigel agreement was signed. Research and Development expense fell USD 17.8 million to USD 46.9 million, with program spending on vepdegestrant down USD 14.2 million, partly offset by higher spending on ARV-027, ARV-6723 and ARV-393 of USD 4.6 million, USD 3.3 million and USD 3.2 million. General and administrative expense declined USD 8.4 million to USD 12.6 million. Loss from operations widened to USD 59.1 million from USD 43.8 million, and interest and other income slipped to USD 5.4 million from USD 9.0 million. Cash runway and pipeline timeline. Cash, cash equivalents, restricted cash and marketable securities stood at USD 558.9 million on September 30, 2026. Cash used in operations over nine months was USD 123.0 million, net of USD 35.0 million received under the Rigel agreement. Management said current resources fund planned operating and Capital expenses into the second half of 2028. Chief Executive Officer Randy Teel said the company is directing spending toward programs backed by early evidence and is entering a period of clinical milestones for its BCL6, polyQ-AR and HPK1 degraders. Dosing began in a Phase 1/2 trial of ARV-6723, an oral HPK1 degrader, and additional ARV-102 biomarker data in Parkinson disease patients were shown at a movement disorders congress. Dated pipeline events against the cash position. Cash, restricted cash and marketable securities of USD 558.9 million compare with USD 685.4 million at year end, a USD 126.5 million decline, while total liabilities fell to USD 93.7 million from USD 284.0 million. Initial ARV-393 dose escalation data were submitted for the American Society of Hematology meeting on December 12 to 15, 2026, with additional monotherapy data and initial glofitamab combination data scheduled for mid-2027. ARV-027 healthy volunteer data are scheduled for the first half of 2027, and initial ARV-6723 monotherapy data for the second half of 2027. Clinical trial applications for an ARV-102 Phase 1b study in progressive supranuclear palsy are scheduled for the European Union in the fourth quarter of 2026 and the United Kingdom in the first quarter of 2027. Download Free Report - Explore 3 Stock Ideas & Industry Insights Unlock 3 stock ideas and key industry insights in its free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice. All investments involve risk - consider independent advice before making any investment decisions. Disclaimer:

Arvinas announces return of Early Career Researcher Award to recognize innovation in targeted protein degradation. October 27, 2026 16:01 ET | Source: Arvinas Inc. - $25,000 monetary award to recognize an emerging researcher or research team advancing targeted protein degradation - - Nominations open November 1, 2026, and close December 31, 2026; winner to be recognized in mid-2027 - NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) - Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the return of the Arvinas Early Career Researcher Award, which recognizes the research of an emerging researcher or research team bringing innovation, new approaches and creative thinking to the field of targeted protein degradation (TPD). Randy Teel, Ph.D., President and Chief Executive Officer of Arvinas, announced the award's return during a company presentation at the Hanson Wade 9th Annual TPD & Induced Proximity Summit. "Scientific progress starts with bold questions and the curiosity to pursue them," said Randy Teel, Ph.D., President and Chief Executive Officer at Arvinas. "As pioneers in targeted protein degradation, we have seen how that curiosity and creative thinking can open new possibilities in drug discovery. By bringing back the Arvinas Early Career Researcher Award, we're recognizing and supporting the work of emerging scientists whose research could help shape the next chapter of TPD." First established to mark 20 years of TPD, the award reflects Arvinas' commitment to championing emerging talent and giving back to the scientific community advancing the field. Being presented for a second time, the award includes a $25,000 monetary prize, with the winner to be formally recognized in mid-2027. Nominations will open November 1, 2026, and must be received by December 31, 2026, at 11:59 p.m. ET. Submissions will be evaluated based on nominees' contributions to innovation in TPD, including novel discoveries, scientific leadership and the application of new approaches or creative thinking to the field. Self-nominations and joint applications are permitted. Researchers in academia, at either the graduate or postdoctoral level at the time of studies conducted and/or published, will be eligible for this award. Full eligibility criteria and application instructions are available here. Only applicants who meet the full eligibility criteria will be considered. About Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROteolysis TArgeting Chimera (PROTAC) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of heterobifunctional protein degrader, which has been outlicensed to Rigel Pharmaceuticals, Inc. for exclusive global development, manufacturing, and commercialization. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular atrophy, also known as Kennedy's disease; and ARV-6723, targeting HPK1 for advanced solid tumors. Arvinas has also advanced ARV-806, targeting KRAS G12D for solid tumors, in the clinic, and previously announced plans to seek an out-licensing agreement for any additional clinical trials of ARV-806, including dose expansion or combination clinical trials. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the potential of, and Arvinas' plans with respect to, its clinical development programs, including ARV-393, ARV-102, ARV-027 and ARV-6723; and Arvinas' plans to seek an out-licensing agreement for any additional clinical trials of ARV-806. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas' strategy, development plans, future operations, prospects, plans, and objectives of management and the statements identified in the prior paragraph, are forward-looking statements. The words "ability," "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "potential," "target," "goal," "aim," "whether," "will," "would," "could," "reliance," "should," "look forward," "seek," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for its product candidates on its current timelines or at all; Arvinas' ability to protect its intellectual property portfolio; Arvinas' reliance on third parties; and other important factors discussed in the "Risk Factors" section of Arvinas' Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent other reports filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas' current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas' views as of any date subsequent to the date of this release.